Cellular and Molecular Neurobiology

, Volume 28, Issue 6, pp 907–913 | Cite as

Cyclin D1 Immunoreactivity in Meningiomas

  • Sanja Milenković
  • Tatjana Marinkovic
  • Milan B. Jovanovic
  • Slavisa Djuricic
  • Ivana I. Berisavac
  • Iva Berisavac
Original Paper


Objective Cyclin D1 is an important nuclear protein required for progression of cells through the G1 phase of the cell cycle. The proliferative potential of meningiomas has been studied using various proliferative markers. However, there have been only few published studies evaluating Cyclin D1 immunoreactivity in meningiomas. Purpose of the study The aim of our study was to analyze the Cyclin D1 expression in meningiomas and correlate it both with proliferation markers Ki67 and PCNA, and with meningiomas of WHO grade. Material and methods We evaluated immunoreactivity for proliferative markers (Cyclin D1, Ki-67, and PCNA) in a consecutive series of 64 meningioma samples obtained from patients who underwent surgical resection because of cerebral or spinal meningiomas. Immunohistochemical staining with Ki-67, PCNA, and Cyclin D1 was performed using the microwave processing procedure and LSAB+ methodology. The number of positive cells for each antibody has been determined and shown in percentage in relation to 1000 counted cells. Results All meningioma samples showed immunostaining for Ki-67, PCNA, and Cyclin D1 antibodies. The Cyclin D1 scores exhibited a close correlation with Ki-67 and PCNA immunostaining (P < 0.01). Some meningiomas (15 cases) showed a combination of nuclear and cytoplasmatic (fine granular) Cyclin D1 immunoreactivity. All proliferative indexes have been in positive correlation with meningioma grade. Conclusion Our comparative study of proliferative markers in meningiomas demonstrated Cyclin D1 as a very useful proliferative marker in meningiomas.


Meningiomas Proliferative indices Cyclin D1 Ki67 PCNA Immunohistochemistry 



The authors wish to thank Prof. Dr. Dubravka Cvetkovic-Dozic and Prof. Milica Skender-Gazibara and Prof. Slobodan Dozic for useful suggestions and helpful discussion of the manuscript. We also thank Milan Gajic for the crucial help with statistical analysis of data.


  1. Abramovich CM, Prayson RA (1998) MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 29:1420–1427PubMedCrossRefGoogle Scholar
  2. Alama A, Barbieri B, Spaziante R, Bruzzo C, Dadati P, Dorcaratto A (2007) Significance of cyclin D1 expression in meningiomas. A preliminary study. J Clin Neurosci 14:355–358PubMedCrossRefGoogle Scholar
  3. Alt JR, Gladden AB, Diehl JA (2001) p21cip1 promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 277:8517–8523PubMedCrossRefGoogle Scholar
  4. Amatya JV, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K (2001) Immunohistochemical study of Ki-67 (MIB-1), p53 Protein, p21WAF1, and p27KIP1 expression in Benign, atypical, and anaplastic meningiomas. Hum Pathol 32(9):970–975PubMedCrossRefGoogle Scholar
  5. Arber N, Gammon MD, Hibshoosh H, Britton JA, Zhang Y, Schonberg JB, Roterdam H, Fabian I, Holt PR, Weinstein B (1999) Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 30:1087–1092PubMedCrossRefGoogle Scholar
  6. Clurman BE, Roberts JM (1995) Cell cycle and cancer. J Natl Cancer Inst 87:1499–1501PubMedCrossRefGoogle Scholar
  7. Daidone MG, Costa A, Silvestrini R (2001) Cell proliferation markers in human solid tumors: assessing their impact in clinical oncology. Methods Cell Biol 64:359–384PubMedCrossRefGoogle Scholar
  8. Diehl JA, ChengM, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499–3511PubMedCrossRefGoogle Scholar
  9. Gijtenbeek MMJ, Boots-Sprenger HES, Franke B, Wesseling P, Jeuken WMJ (2005) Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol 74:261–266PubMedCrossRefGoogle Scholar
  10. Holland TA, Elder J, McCloud JM, Hall C, Deakin M, Fryer AA et al (2001) Subcellar localization of cyclin D1 protein in colorectal tumours is associated with p21WAF1/CIP1265 expression and correlates with patient survival. Int J Cancer (Pred Oncol) 95:302–306CrossRefGoogle Scholar
  11. Hsu DW, Efird JT, Headley-White ET (1998) MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 24:441–452PubMedCrossRefGoogle Scholar
  12. Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26:461–469PubMedCrossRefGoogle Scholar
  13. Karamitopoulou E, Perentes E, Tolnay M, Probst A (1998) Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 29:140–145PubMedCrossRefGoogle Scholar
  14. Kato JY, Matsuoka M, Strom DK, Sherr CJ (1994) Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol 14(4):2713–2721Google Scholar
  15. Korshuno A, Shishkina L, Golanov A (2002) DNA Topoisomerase II-a and Cyclin A. Immunoexpression in meningiomas and its prognostic significance an analysis of 263 cases. Arch Pathol Lab Med 126:1079–1086Google Scholar
  16. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberto N, Albanese V (2000) Correlation between histological grade, MIB-1, p53 and recurrence in 69 completely resected primary intracranial meningiomas. Pathol Res Pract 196:483–488PubMedGoogle Scholar
  17. Lebe B, Sağol Ö, Ulukus Ç, Çoker A, Sedat Karademir S, Astarcioglu H, Küpelioğlu A, Astarcioğlu I, Obuz F (2004) The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathol Res Pract 200:389–396PubMedCrossRefGoogle Scholar
  18. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ (2000) Meningiomas: pathology and genetics of tumours of the nervous system. In: Kleihues P, Cavenee WK (eds) World Health Organization classification of tumours. IARC Press, Lyon, pp 176–184Google Scholar
  19. Madsen C, Schroeder HD (1997) Ki-67 immunoreactivity in meningiomas. Clin Neuropathol 16:137–142PubMedGoogle Scholar
  20. Marks SM, Whitewell HL, Lye RH (1986) Recurrence of meningiomas after operation. Surg Neurol 25:436–440PubMedCrossRefGoogle Scholar
  21. Milenkovic S, Berisavac I, Bojović V, Orlić M, Stanković D, Simić A (2005) Multiple spinal meningiomas with positive PR-case report. Mater Med 21(2):105–109Google Scholar
  22. Motokura T, Keyomarsi K, Kronenberg HM, Arnold A (1992) Cloning and characterization of human Cyclin D3, a cDNA closely related in sequence to the PRADI/cyclin D1-proto-oncogene. J Biol Chem 267(28):20412–20415PubMedGoogle Scholar
  23. Nakaguchi H, Fujimaki T, Matsuno A, Matsuura R, Asai A, Suzuki I et al (1999) Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer 85:2249–2254PubMedCrossRefGoogle Scholar
  24. Pagano M, Theodoras AM, Tam SW, Draetta GF (1994) Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8:1627–1639PubMedCrossRefGoogle Scholar
  25. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1998) The prognostic significance of MIB-1, p53 and flow-cytometry in completely resected primary meningiomas. Cancer 82:2262–2269PubMedCrossRefGoogle Scholar
  26. Sato K, Schauble B, Kleihues P, Ohgaki H (1996) Infrequent altera-tions of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer 66(3):305–308PubMedCrossRefGoogle Scholar
  27. Sherr CJ (1995) D-type cyclins. Trends Biochem Sci 20:187–190PubMedCrossRefGoogle Scholar
  28. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatr 20:22–39PubMedCrossRefGoogle Scholar
  29. Sourisseau T, Georgiadis A, Tsapara A, Ali RR, Pestell R, Matter K, Balda SM (2006) Regulation of PCNA and Cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA. Mol Cell Biol 26(6):2387–2298PubMedCrossRefGoogle Scholar
  30. Takahashi AJ, Ueba T, Hashimoto N, Nakashima Y, Katsuki N (2004) The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg Neurol 61:149–156PubMedCrossRefGoogle Scholar
  31. Takeuchi H, Kubota T, Kabuto M, Kitai R, Nozaki J, Yamashita J (1997) Prediction in recurrence of histologically benign meningiomas: PCNA and Ki-67 immunohistochemical study. Surg Neurol 48:501–506PubMedCrossRefGoogle Scholar
  32. Torp SH, Lindboe CF, Granli US, Moen TM, Nordtomme T (2001) Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Clin Neuropathol 20:190–195PubMedGoogle Scholar
  33. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK (2001) Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53 wafl pRb and Ki67. Br J Cancer 84:270–275PubMedCrossRefGoogle Scholar
  34. Xiong Y, Zhang H, Beach D (1992) D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505–514PubMedCrossRefGoogle Scholar
  35. Xiong Y, Zhang H, Beach D (1993) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7:1572–1583PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sanja Milenković
    • 1
  • Tatjana Marinkovic
    • 2
  • Milan B. Jovanovic
    • 3
  • Slavisa Djuricic
    • 4
  • Ivana I. Berisavac
    • 5
  • Iva Berisavac
    • 6
  1. 1.Department of Clinical PathologyClinical Hospital Centre ZemunBelgradeSerbia and Montenegro
  2. 2.Medical Faculty FocaUniversity of East SarajevoSarajevoBosnia and Herzegovina
  3. 3.OthorinolaryngologyClinical Hospital Centre ZemunBelgradeSerbia and Montenegro
  4. 4.Mother and Child Institute “Vukan Cupic”BelgradeSerbia and Montenegro
  5. 5.Medical FacultyInstitute of NeurologyBelgradeSerbia and Montenegro
  6. 6.NeurosurgeryClinical Hospital Centre ZemunBelgradeSerbia and Montenegro

Personalised recommendations